SA PRO
Free Account
Allogene Therapeutics, Inc.ALLONASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 68% recommend buying.

Consensus Rating
Buy
28 analysts·High coverage
68%
Rating Distribution
Strong Buy
00%
Buy
1968%
Hold
725%
Sell
27%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 1451% higher.

Bear Case
$7.00
+274%
Consensus
$29.00
+1451%
Bull Case
$55.00
+2841%
Price Range28 analysts
Low
Consensus
High
$7.00
$55.00
Current Target
Current Price
$1.87
Upside to Target
$27.13

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

May 16, 2024H.C. Wainwright
Allogene (ALLO) PT Lowered to $9 at H.C. Wainwright
Target:$9.00
+202.0%from $2.98
May 14, 2024B.Riley Financial
Allogene (ALLO) PT Lowered to $7 at B.Riley
Target:$7.00
+141.4%from $2.90
Jun 13, 2022Robert W. Baird
Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird
Target:$11.00
+12.9%from $9.74
Jan 3, 2022Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
Target:$35.00
+128.9%from $15.29
Dec 3, 2021Canaccord Genuity
Allogene Therapeutics clinical hold could be lifted shortly, says Canaccord
Target:$55.00
+212.1%from $17.62
Oct 8, 2021Bank of America Securities
Allogene (ALLO) PT Lowered to $32 at BofA Securities
Target:$32.00
+143.7%from $13.13
Oct 8, 2021Roth Capital
Allogene Therapeutics price target lowered to $35 from $60 at Roth Capital
Target:$35.00
+166.6%from $13.13
Oct 8, 2021Oppenheimer
Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer
Target:$40.00
+204.6%from $13.13
Oct 8, 2021Jefferies
Allogene (ALLO) PT Lowered to $30 at Jefferies
Target:$30.00
+128.5%from $13.13
Sep 23, 2021Raymond James
Allogene Therapeutics upgraded to Outperform from Market Perform at Raymond James
Target:$36.00
+30.2%from $27.64

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance